These label-free impedimetric immunosensors can be possibly useful for monitoring the response to lenalidomide in MM patients by detecting IKZF1 and IKZF3, and maybe later applied for monitoring different immunomodulators or therapeutic agents. Here, IKZF3 is linked to Miyoshi myopathy.